[1] Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J]. CA Cancer J Clin, 2010, 60(5): 277-300.
[2] Samrao D, Wang D, Ough F, et al. Histologic parameters predictive of disease outcome in women with advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy[J]. Transl Oncol, 2012, 5(6): 469-474.
[3] Costanzo RV, ViláOrtíz GJ, Perandones C, et al. Anp32e/Cpd1 regulates protein phosphatase 2A activity at synapses during synaptogenesis[J]. Eur J Neurosci, 2006, 23(2): 309-324.
[4] de Bont JM, Kros JM, Passier MM, et al. Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis[J]. Neuro Oncol, 2008, 10(5): 648-660.
[5] Walker BA, Leone PE, Chiecchio L, et al. A compendium of myelomaassociated chromosomal copy number abnormalities and their prognostic value[J]. Blood, 2010, 116(15): e56-65.
[6] Tsukamoto Y, Uchida T, Karnan S, et al. Genomewide analysis of DNA copy number alterations and gene expression in gastric cancer[J]. J Pathol, 2008, 216(4): 471-482.
[7] Reilly PT, Afzal S, Wakeham A, et al. Generation and characterization of the Anp32edeficient mouse[J]. PLoS One, 2010, 5(10): e13597.
[8] Tavazoie SF, Alarcón C, Oskarsson T, et al. Endogenous human microRNAs that suppress breast cancer metastasis[J]. Nature, 2008, 451(7175): 147-152.
[9] Andersen CL, Christensen LL, Thorsen K, et al. Dysregulation of the transcription factors SOX4, CBFB and SMARCC1 correlates with outcome of colorectal cancer[J]. Br J Cancer, 2009, 100(3): 511-523.
[10] Du Y, Spence SE, Jenkins NA, et al. Cooperating cancergene identification through oncogenicretrovirusinduced insertional mutagenesis[J]. Blood, 2005, 106(7): 2498-2505. |